OVID (Ovid Therapeutics Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by OVID officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-08 | Charles Ross Carter | Chief Financial Officer | A | — | — |
| 2026-06-17 | Anna Greka | Director | A | — | — |
| 2026-04-09 | STELIOS PAPADOPOULOS | Director | A | — | — |
| 2026-04-09 | Bart Friedman | Director | A | — | — |
| 2026-04-09 | Kevin Joseph Fitzgerald | Director | A | — | — |
| 2026-03-25 | JEREMY M LEVIN | Executive Chairman | M | — | — |
| 2026-03-02 | JEREMY M LEVIN | Director | A | — | — |
| 2026-03-02 | STELIOS PAPADOPOULOS | Director | A | — | — |
| 2026-03-02 | BARBARA GAYLE DUNCAN | Director | A | — | — |
| 2026-03-02 | Bart Friedman | Director | A | — | — |
| 2026-03-02 | Jeffrey A Rona | CBFO | MIXED | — | — |
| 2026-03-02 | MARGARET A. ALEXANDER | President and CEO | Sell | — | — |
| 2026-03-02 | Karen Bernstein | Director | A | — | — |
| 2026-03-02 | Kevin Joseph Fitzgerald | Director | A | — | — |
| 2026-01-05 | MARGARET A. ALEXANDER | President and CEO | A | — | — |
| 2025-12-18 | JEREMY M LEVIN | CEO | C | — | — |
| 2025-12-09 | TAKEDA PHARMACEUTICAL CO LTD | 10%+ Owner | C | — | — |
| 2025-06-18 | Karen Bernstein | Director | A | — | — |
| 2025-06-18 | Bart Friedman | Director | A | — | — |
| 2025-06-18 | Kevin Joseph Fitzgerald | Director | A | — | — |
| 2025-06-18 | Barbara Gayle Duncan | Director | A | — | — |
| 2025-03-04 | STELIOS PAPADOPOULOS | Director | A | — | — |
| 2025-02-28 | Jeffrey A Rona | CBFO | Sell | — | — |
| 2025-02-28 | MARGARET A. ALEXANDER | President and COO | Sell | — | — |
| 2025-02-24 | MARGARET A. ALEXANDER | President and COO | A | — | — |
| 2025-02-24 | Jeffrey A Rona | CBFO | A | — | — |
| 2025-02-24 | JEREMY M LEVIN | CEO | A | — | — |
| 2025-01-29 | MARGARET A. ALEXANDER | President and COO | Buy | — | — |
| 2024-12-16 | Karen Bernstein | Director | A | — | — |
| 2024-12-16 | Kevin Joseph Fitzgerald | Director | A | — | — |
| 2024-12-16 | Barbara Gayle Duncan | Director | A | — | — |
| 2024-12-16 | Bart Friedman | Director | A | — | — |
| 2024-09-11 | MARGARET A. ALEXANDER | President and COO | A | — | — |
| 2024-08-01 | Jeffrey A Rona | CBFO | A | — | — |
| 2024-03-20 | JEREMY M LEVIN | CEO | Buy | — | — |
| 2024-02-26 | Karen Bernstein | Director | A | — | — |
| 2024-02-26 | Robert Michael Poole | Director | A | — | — |
| 2024-02-26 | Barbara Gayle Duncan | Director | A | — | — |
| 2024-02-26 | Jeffrey A Rona | CBFO | A | — | — |
| 2024-02-26 | JEREMY M LEVIN | CEO | A | — | — |
| 2024-02-26 | Jason Tardio | Chief Operating Officer | A | — | — |
| 2024-02-26 | Thomas Michael Perone | General Counsel, Secretary | A | — | — |
| 2024-02-26 | Kevin Joseph Fitzgerald | Director | A | — | — |
| 2024-02-26 | Bart Friedman | Director | A | — | — |
| 2024-02-14 | JEREMY M LEVIN | CEO | G | — | — |
| 2023-12-06 | JEREMY M LEVIN | CEO | G | — | — |
| 2023-02-27 | Karen Bernstein | Director | A | — | — |
| 2023-02-27 | JEREMY M LEVIN | CEO | A | — | — |
| 2023-02-27 | Kevin Joseph Fitzgerald | Director | A | — | — |
| 2023-02-27 | Robert Michael Poole | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 8,781,996 | — |
| — | 10%+ Owner | 5,750,000 | — |
| — | President and CSO | 4,400,337 | — |
| — | Executive Chairman | 3,770,509 | — |
| — | President and CMO | 726,823 | — |
| — | Director | 217,578 | — |
| — | Chief Financial Officer | 94,375 | — |
| — | CBFO | 88,188 | — |
| — | President and CEO | 61,750 | — |
| — | General Counsel, Secretary | 28,125 | — |
| — | Chief Operating Officer | 28,125 | — |
| — | Director | 20,000 | — |
| — | Director | 17,578 | — |
| — | Director | 8,789 | — |
| — | Director | 5,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OVID quote page; the site-wide leaderboard is on the insider transactions hub.